DBV Technologies | DBVT - Operating Profit


DBV Technologies reported $-34.28M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
Amarin USD -2.26M 564K Dec/2025
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
DBV Technologies USD -34.28M 6.83M Sep/2025
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Galectin Therapeutics USD -11.29M 1.64M Jun/2024
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
Insmed USD -200.28M 49.43M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026